STING1 and neoplasm: A particularly compelling therapeutic synergy exists between STING agonists and DNA damage response (DDR)‐targeting agents, such as Rad3‐related protein inhibitors[32e] and poly(ADP‐ribose) polymerase (PARP) inhibitors.[126] These agents induce DNA damage, accumulation, leading to the generation of neoantigens and subsequent STING pathway activation, thereby enhancing tumor immunogenicity.